Aziyo Biologics, Inc

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates

Positive meeting with FDA provides clarity for CanGaroo ® RM clearance

Aziyo Biologics Reports Strong Third Quarter 2022 Revenue

Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and Interim Chief Executive Officer and Yvette Heinrichson named Chief Financial Officer Closed three new transactions during the quarter, totaling $57.5 million of committed capital Subsidiary Enteris achieved $5.0 million milestone with Cara Therapeutics; SWK will retain $2.5 million Repurchased 34,463 shares of common stock during the quarter for a total cost of $0.6 million Third quarter 2022 GAAP net income was $6.6 million or $0.51 per diluted share Finance Receivables Segment Update Third quarter 2022 GAAP net income was $6.6 million, compared with $2.2 million for the third quarter 2021.

SWK Holdings Corporation Announces Financial Results for Third Quarter 2022

SILVER SPRING, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced that it will release third quarter 2022 financial results after market close on Monday, November 14, 2022. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics to Report Third Quarter 2022 Financial Results on November 14, 2022

Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aziyo Biologics, Inc. (AZYO) Soars 11.7%: Is Further Upside Left in the Stock?

Senior team enhanced to advance Aziyo's commercial and financial objectives Senior team enhanced to advance Aziyo's commercial and financial objectives

Aziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key Markets

Renown Pioneer in Regenerative Medicine to Lead Company's Pipeline Development Initiatives Renown Pioneer in Regenerative Medicine to Lead Company's Pipeline Development Initiatives

Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer

SILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 10:30 am ET / 7:30 am PT.

Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Leigh Salvo - IR Kevin Rakin - Executive Chairman Randy Mills - CEO Matthew Ferguson - CFO Conference Call Participants Josh Jennings - Cowen David Rescott - Truist Ross Osborn - Cantor Fitzgerald Operator Good day. And thank you for standing by.

Aziyo Biologics (AZYO) CEO Randy Mills on Q2 2022 Results - Earnings Call Transcript

Provides Additional Working Capital to Further Fund Growth Initiatives Provides Additional Working Capital to Further Fund Growth Initiatives

Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings

SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis. Dr. Mills, who is internationally recognized for his contributions to the field of regenerative medicine, has served as the Company's interim CEO since June 2022.

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will release second quarter 2022 financial results after market close on Thursday, August 11, 2022. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022

Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.

Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?

Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?

SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced Aziyo co-founder C. Randal (Randy) Mills, Ph.D., has been appointed interim president and CEO. Ronald Lloyd will step down from these positions but will remain with the company through the end of the third quarter to assist with the transition. Aziyo co-founder Kevin Rakin has also assumed the role of executive chairman.

Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO

Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Ronald Lloyd – President and Chief Executive Officer Matthew Ferguson – Chief Financial Officer Leigh Salvo – Investor Relations, Gilmartin Group, LLC Conference Call Participants David Rescott – Truist Securities Operator Thank you for standing by and welcome to Aziyo Biologics Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2022 Results - Earnings Call Transcript

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates

SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today provided a business update and reported financial results for the first quarter March 31, 2022.

Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results

SILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter 2022 earnings results after market close on Monday, May 9, 2022. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

Call to Highlight the Use and Benefits of Aziyo's CanGaroo Envelope for Implantable Electronic Devices Call to Highlight the Use and Benefits of Aziyo's CanGaroo Envelope for Implantable Electronic Devices

Aziyo Biologics Announces Upcoming KOL Call Hosted by Cowen

SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2021 Results - Earnings Call Transcript

SILVER SPRING, Md., March 03, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results

SILVER SPRING, Md., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 42nd Annual Cowen Health Care Conference.

News for Aziyo Biologics, Inc Stock (AZYO)